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To study survivin gene expression in APL cells and to explore its correlation with clinical manifestations. PML/RARα and survivin
mRNA expression were analysed using RT-PCR. By treatment of ATRA, the survivin mRNA expression in NB4 cells gradually
decreased with time and was almost undetectable in the 72th hour. Survivin was expressed in 67% of the 36 APL cases (de novo
andrelapsepatients)withPML/RARαfusiongeneexpression.However,in22casesofremissionstagepatientswithoutPML/RARα
fusiongeneexpression,survivinwasexpressedin36%.ThesurvivinmRNAexpressionpositiverateindenovoandrelapsegroups,
and PML/RARα fusion gene L-type positive groups, was obviously higher than those in remission period groups and was signifi-
cantly lower than those in acute leukemia groups. In 36 cases of de novo and relapse APL patients, all cases could obtain complete
remission, irrespective of the survivin expression. APL patients expressed with survivin mRNA had DIC and serious infection
(one patient died). The clinical symptom included slight skin or mucosa bleeding, fever, and asthenic for patients without the
survivin mRNA expression. Later, two cases of APL patients with the survivin mRNA expression were treated by ATRA, induction
diﬀerentiation sign in their peripheral blood and bone marrow ﬁgure was not obvious. It was concluded that the survive gene
expression was lower in APL than those in any other types of leukemia, thus closely associated with clinical manifestation.
1.Introduction
It has been shown that PML-RAR chimeric protein, as a re-
sult of the speciﬁc chromosome translocation t(15; 17), plays
a central role in acute promyelocytic leukemia (APL) path-
ogenesis. Clinically, APL is sensitive to antileukemic chemo-
therapy, to the diﬀerentiation therapy with all-trans retinoid
acid (ATRA), and to arsenic compounds including arsenic
trioxide (As2O3) and arsenic disulﬁde.
Several multicenter clinical trials combining ATRA and
chemotherapy have further improved the survival of APL
patients. Arsenic compounds have allowed not only a high
complete remission (CR) rate, but also relatively long-term
survival in a signiﬁcant proportion of patients.
Survivin, a member of the inhibitors-of-apoptosis (IAP)
family of proteins, is present during fetal development but is
undetectable in terminally diﬀerentiated adult tissues. How-
ever, survivin is prominently expressed in transformed cell
lines,inmostcommonhumancancers,andinapproximately
50% of high-grade non-Hodgkin lymphomas. Survivin sup-
presses apoptosis induced by Fas, Bax, caspases, and anti-
cancer drugs. Conversely, the downregulation of survivin
by antisense oligonucleotides induces apoptosis in vitro.
Although survivin protein lacks the ability to directly inhibit
caspase-3, it binds quantitatively to a new IAP-inhibiting
protein, Smac/Diablo, raising the possibility that it might
suppress caspases indirectly by freeing other IAP family
membersfromtheconstraintsofthisprotein.Takentogether,
these studies support the notion that survivin exerts an anti–
apoptotic eﬀect.
Our prior research report showed that survivin gene
expression levels in acute leukemia cells were signiﬁcantly
higherthanthoseinnormalbonemarrowmononuclearcells
(82% versus 33.3%, P<0.05). Among 5 cases of APL, 4 cases
did not express survivin. In 4 cases of APL, which the surviv-
in mRNA expression were negative, after being treated by
ATRA, 3 cases of APL achieved bone marrow remission
(BMR), the APL patient of survivin positive expression died2 The Scientiﬁc World Journal
of DIC [1]. Accordingly, is there obvious diﬀerence between
APL and other leukaemia in survivin genetic transcription
level? In the present study, survivin transcription level in
APLs had been investigated by means of a reverse transcrip-
tase polymerase chain reaction (RT-PCR) analysis. Further-
more, the prognostic values of survivin expression in these
patients were also assessed and evaluated.
2. Methods
2.1.NB4CellLineCulture. HumanNB4celllinesofAPLwas
cultured in RPMI1640 (Invitrogen, USA) medium contain-
ing 10% newborn calf serum in a humidiﬁed atmosphere of
95%air/5%CO2 at37◦C.Tominimizespontaneousnucleos-
omal DNA fragmentation and apoptosis, cells were main-
tained at densities <5 × 105 cells/mL by adjusting cell con-
centrations daily with adding fresh culture medium and
corresponding concentrations of compounds while neces-
sary. NB4 cells (1 × 105 cells/mL) were treated with ATRA
(1μmol/L) for 24, 48, 72 hours and then harvested. The
survivin mRNA expression were analysed using reverse tran-
scriptase polymerase chain reaction (RT-PCR) technique.
2.2. Patient Characteristics and Primary Samples. There were
36APLpatientshospitalizedorservedwithout-patientclinic
(34 newly diagnosed and 2 relapsed). The patients aged from
9 to 72 years (average, 40.5 years); there were 17 men and 19
were women. The remission period of APL patients involved
22 cases. The patients aged from 3 to 57 years (average, 30
years) among 10 male and 12 female, the remission duration
lasted from 1 to 72 months (average, 37 months). Diagnosis
was based on MICM typing standard (among which 20 cases
were M3a and 16 M3b). Patients of de novo APL were ﬁrst
treated with ATRA. When the peripheral white blood cells
ascend to 10.0 × 109/L, HA (homoharringtonine and cytara-
bine) chemotherapy regimen were used. The APL patients of
relapse and ATRA drug resistance were applied with As2O3.
The bone marrow remission rate (BMR) was acted as thera-
peutic eﬀect index. The acute leukemia (AL) groups were 23
cases (M1,3, M2,6, M4−5,2, ALL-L1,4, ALL-L2,8). Patient aged
from 20 to 64 years (average, 42 years); there were 16 men
and 7 women.
Bone marrows were obtained from patients with APL
and normal donors after informed consents were obtained
according to institutional guidelines. Mononuclear cells were
puriﬁed by Ficoll-Hypaque (Sigma Chemical, St Louis, MO)
density-gradient centrifugation.
2.3. RNA Extraction and PCR Ampliﬁcation of PML-RAR-α
[2] and Survivin RNAs. The concrete procedure was shown
in[2]2×106 NB4cellsweretwicewashedwithPBSsolution,
and RNA was isolated with Trizol solution (Gibco, USA),
according to the manufacturer’s instructions, eluted with
50μL of diethylpyrocarbonate water containing 50 units of
RNase inhibitor (Boehringer Mannheim, Indianapolis, IN).
RNA concentration was determined by spectrophotometry
and adjusted to a concentration of OD260/OD280 ≥ 1.7.
Two microgram total RNA cases were reverse transcribed
with survivin. RNA from NB4 cells and bone marrow mon-
onuclear cells of APL patients were puriﬁed by using the
Ultraespec RNA kit (Biotecx Laboratories, Houston, TX),
accordingtothemanufacturer’sinstructions,andelutedwith
50μL of diethylpyrocarbonate water containing 50 units of
RNase inhibitor (Boehringer Mannheim, Indianapolis, IN).
RNA was reverse transcribed by Moloney murine leukemia
virus reverse transcriptase (Promega company) and 0.5μg
oligo(T)18. Incubation was performed at 70◦C for 5min,
42◦Cf o r6 0m i n ,a n d7 0 ◦C for 15min. CDNA was then am-
pliﬁed by PCR cDNA 2μL, 20pmol/L forward and reverse
primer 1μL each, 10mM dNTP 0.5μL, 10 × PCR buﬀer
2.5μL, 25mM MgCl 21.5μL, TaqDNA polymerase 2U, total
volume 25μL). The sequence of the sense primer of survivin
was 5 -ctttctcaaggaccaccgcatc-3  and the antisense primer
was 5 -caatccatggcagccagctgc-3  as of survivin. Cycling con-
ditions were as follows: initial denaturation at 94◦Cf o r
2min, followed by 39 cycles at 94◦C for 45 seconds, 61◦C
for 1min, 72◦ for 1min, and ﬁnally 72◦Cf o r5m i n u t e s .
Identical PCR conditions were used to amplify the beta-
actin cDNA that was used as an internal control; the sense
and antisense primer sequences used for beta-actin were 5 -
cgctgcgctggtcgtcgaca-3  and 5 - gtcacgcacgatttcccgct-3 .P C R
ampliﬁcations were performed in duplicate using indepen-
dent cDNA preparations. Tubes containing all ingredients
exceptforthecDNAtemplateswereincubatedinallrunsand
served as negative controls. Ampliﬁed cDNAs were separated
on1.5%agarosegels,andthebandswerevisualizedbyethid-
iumbromideandphotographedwithaPolaroidcamera(Po-
laroid, Cambridge, MA).
2.4. Statistical Analysis. T h eS P S S1 0 . 0s o f t w a r ef o rW i n d o w s
was used for analysis. The statistical signiﬁcance of inter-
group diﬀerences was evaluated by Fisher’s exact test. Values
of P<0.05 were considered statistical signiﬁcance.
3. Results
3.1. Expression of Survivin mRNA in NB4 Cells Treated with
ATRA. As shown in Figure 1, the survivin mRNA expression
was detected in NB4 cells. By treatment of 1μmol/L ATRA,
survivin mRNA expression in NB4 cells gradually decreased
with time and almost undetectable in the 72th hour point.
3.2. Expression of Survivin mRNA in the de Novo, Relapse
Groups and Remission Period Groups of APL Patients. The
resultswere showninTable 1.Thepositive andnegativerates
of survivin mRNA expression were 67% and 33%, respec-
tively, in all 36 cases of de novo and relapse APL patients
whosePML/RARα fusiongeneexpressionwaspositive.There
were also 22 cases of remission patients whose PML/RARα
fusion gene expression was negative, and the positive and
negative rates of survivin mRNA expression were 36% and
64%, respectively. The survivin mRNA expression positive
rate in the de novo and relapse groups, and PML/RARα
fusion gene L-type positive groups was obviously higher
than those in remission period groups (P<0.05) and wasThe Scientiﬁc World Journal 3
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Figure 1: Survivin mRNA expression of NB4 cells treated by ATRA
at diﬀerent time.
Table 1: The results of survivin mRNA expression in de novo,
relapse, and remission APL.
Group N survivin-mRNA expression
positive P value
(1) de novo and relapse∗ 36 24 (67%)
Lt y p e( + ) # 28 19 (68%)
S type (+) 8 5 (63%)
(2) remission& 22 8 (36%)
(3) acute leukemia 23 21 (91%)
Compared by remission ∗x2 = 5.07, P = 0.024; #x
2
= 4.92, P = 0.027;
compared by acute leukemia ∗x2 = 4.71, P = 0.03; &x
2
= 14.81,P = 0.00.
obviously lower than those in acute leukemia grougs (P<
0.05, <0.001).
3.3. The Relation between Survivin mRNA Expression and
Clinical Manifestation in APL Patients. Regardless the sur-
vivinmRNAexpressionwaspositiveornegativein36casesof
de novo and relapse APLpatients, allof 36 cases couldobtain
complete remission. The APL patients with positive survivin
mRNA expression had combination of DIC and serious in-
fection (one patient died). The clinical symptom had slight
skin or mucosa bleeding, fever, and asthenic for patients
without the survivin mRNA expression. Afterwards 2 APL
patients with the survivin mRNA expressed were treated by
ATRA, induction diﬀerentiation sign in their peripheral
blood and bone marrow ﬁgure was not obvious. It was con-
cluded that the survivin gene positive expression rate was
lower in acute promyelocytic leukemia than those in any
other types of leukemia and was related to clinical manifes-
tation.
4. Discussion
First of all, the survivin mRNA expression of bone marrow
mononuclear cells in acute leukemia (except APL) was ex-
amined. The result showed that the survivin mRNA was
expressedinoutof23cases(91%),whichwasconsistentwith
Carter et al’.s [3] report showing the survivin expressed in
88.9% of acute myelocytic leukemia (AML).
Our earlier research has demonstrated that four of ﬁve
patients with APL who did not express survivin in the bone
marrow mononuclear cells had milder clinical symptoms.
The patient died of DIC eventually [1]. Is it true that his cell
biological behaviour of APL is signiﬁcantly unique?
It is known that APL represents a unique model in terms
of the biological and clinical features. The complete remis-
sion rate reachs up to 90% after diﬀerentiated therapies with
all-trans retinoid acid (ATRA). Arsenic compounds includ-
ing arsenic trioxide (As2O3) and arsenic disulﬁde had al-
lowed not only a high complete remission (CR) rate, but also
relatively long-term survival. Are these phenomenons asso-
ciated with antiapoptotic gene surviving? Up to now, few
reports are available about survivin gene expression in APL.
The survivin mRNA expression of bone marrow mononu-
clear cell was analyzed in 36 cases of de novo and relapse
APLs. As bone marrow samples from other types’ acute leu-
kemia were also analyzed, the result indicated that survivin
mRNA expression rate of de novo and relapse APLs were
obviously lower (67% versus 91%, P = 0.03, more lower in
remission patients (67% versus 36%, P = 0.03).
Many research results have demonstrated that the sur-
vivin gene expression in tumour tissue is correlated to clinic
prognosis. A potential distribution and prognostic signiﬁ-
cance of survivin in patients with de novo acute myeloid
leukaemia (AML) was investigated by Adida et al. [4]. By
immunoﬂuoresence of bone-marrow specimens and periph-
eralbloodmononuclearcells,survivinwasdetectedin75out
of 125 interpretable AML cases (60%). There was no signif-
icant diﬀerence in complete remission rate or overall sur-
vival between survivin-positive and survivin-negative AML
patients. However, survivin expression became an indepen-
dent prognostic factor for survival. These data suggest that
survivinexpressionmaybeconsideredasanewunfavourable
prognostic factor of de novo AML and suggest a role for
apoptosis inhibition in inﬂuencing disease outcome. Of the
222 patients with diﬀuse large B-cell lymphomas studied
[5], 134 (60%) revealed survivin expression in virtually all
tumor cells by immunohistochemistry. The overall 5-year
survival rate was signiﬁcantly lower in patients with survivin
expression than in those without. Multivariate analysis in-
corporating prognostic factors from the International Prog-
nostic Index (IPI) identiﬁed survivin expression as an inde-
pendent predictive parameter on survival in addition to
LDH, stage, and ECOG scale.
A second analysis incorporating IPI as a unique param-
eter demonstrated that survivin expression remained as a
prognostic factor for survival independently of IPI. Survivin
expressionmaybeconsideredanewunfavourableprognostic
factor of diﬀuse large B-cell lymphoma. 36 cases of initial
relapse APL and 22 cases of remission were followed up for
more than three years. Because of deﬁcient time, the corre-
lation between survivin mRNA expression and clinical prog-
nosis was not observed.
Our study indicated that the survivin over-expression
was detected in NB4 cells. By treatment of ATRA, survivin
mRNA expression in NB4 cells gradually deceased with time
and almost could not be detected in the 72th hour. The other
research had shown that cytokine stimulation increased sur-
vivin expression in leukemic cell lines and in primary AML
samples [3]. In cultured primary samples, single-cytokine
stimulation substantially increased survivin expression in
comparison with control cells, and the combination of G-
CSF,GM-CSF,andSCFincreasedsurvivinlevelsevenfurther.
Conversely, all-trans retinoic acid signiﬁcantly decreased
survivin protein levels in HL-60, OCI-AML3, and NB-4
cells within 96 hours paralleled to the induction of mye-
lomonocytic diﬀerentiation. These results demonstrate that4 The Scientiﬁc World Journal
hematopoietic cytokines exert their antiapoptotic and mito-
genic eﬀects and that survivin obviously correlates with cell
diﬀerentiation. Accordingly, it was concluded that if tumour
cells were induced and diﬀerentiated to mature, the survivin
mRNA expression would have been downregulated. The dif-
ferentiation level of APL cells is higher than other types’
leukemic cells. Accordingly, the survivin mRNA expression
of APL cells is lower. The researcher has proved that ATRA
treatment prior to chemotherapy may improve the CR rate
in patients with de novo AML, which seems to be related to
its beneﬁcial eﬀect on multidrug resistance [6].
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